Biomedical subjects

A Skopelitou

Publications and source records attributed to A Skopelitou.

21 records · Page 2Linked to original sources

PubMedDate not supplied

Expression of C-myc p62 oncoprotein in multiple myeloma: an immunohistochemical study of 180 cases.

The immunohistochemical expression of C-myc p62 oncoprotein was investigated using the immunoperoxidase method and the monoclonal antibody (Mab) MYC 1-9E10 in bone marrow paraffin sections. 180 cases of multiple myeloma (MM) were studied. C-myc expression was found to correlate well with the grade of malignancy, type of myeloma and tumor cell burden (p < 0.001). A relationship was also observed between C-myc p62 and IgA-secreting myelomas. It was found that intermediate grade myelomas are heterogeneous as far as C-myc expression is concerned. Our findings strongly suggest that C-myc might be involved in myelomutagenesis. The evaluation of its expression in MM may be helpful in determining the grade of malignancy and possibly the biological behaviour of this tumor.

Antibodies, Monoclonal↗

PubMedDate not supplied

Topographical immunohistochemical expression of bcl-2 protein in human liver lesions.

Immunolocalization of the bcl-2 protein was investigated in 60 hepatocellular carcinomas, 10 cholangiocarcinomas. 15 metastatic adenocarcinomas as well as in 37 non-neoplastic liver lesions. The three-step immunoperoxidase method was performed in archival, routinely processed material. bcl-2 protein was not identified either in neoplastic, dysplastic or normal hepatocytes, whereas it was observed in bile ductules and small bile duct epithelia, but not in the epithelium lining large bile ducts. All cases of cholangiocarcinoma and 60% of metastatic adenocarcinomas were bcl-2 positive. bcl-2 appears to be an additional marker in distinguishing hepatocellular carcinoma from cholangiocarcinoma or metastatic adenocarcinoma. Also, bcl-2 does not seem to be involved in human liver hepatocyte survival.

Adenocarcinoma↗

PubMedDate not supplied

p53 DO-1 immunohistochemical overexpression in premalignant and malignant cervical lesions.

One hundred-fourteen cervical lesions, including paraffin sections from benign, premalignant and malignant cervical tissue specimens were examined immunohistochemically for overexpression of p53 protein, using the p53 DO-1 monoclonal antibody (MoAb). p53 overexpression was observed in 66% of premalignant cervical lesions and in 90% of invasive squamous cell carcinomas. The difference in p53 positive lesions of premalignant and malignant cervical lesions was statistically very significant (p < 0.001) and the difference between CIN1 and CIN2 and CIN3 statistically significant (p < 0.01). Our results indicate that p53 overexpression may be involved at an early stage in cervical carcinogenesis.

Antibodies, Monoclonal↗